Claims for Patent: 10,159,759

Summary for Patent: 10,159,759

Title:	Pet tracer for imaging of neuroendocrine tumors
Abstract:	There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
Inventor(s):	Kjaer; Andreas (Frederiksberg, DK), Knigge; Ulrich (Kobenhavn O, DK), Hojgaard; Liselotte (Kobenhavn O, DK), Rasmussen; Palle (Roskilde, DK)
Assignee:	SOMSCAN APS (Frederiksberg, DK)
Application Number:	14/241,958
Patent Claims:	1. A method of diagnosing a neuroendocrine tumor in a radiographic imaging method, the method comprising contacting cells or tissues with a compound of Formula I or a pharmaceutically acceptable salt thereof ##STR00003## wherein the compound is administered with a target dose in the range of 150-250 MBq, and making a radiographic image for detecting the compound. 2. A method of claim 1, wherein the compound is administered with a target dose in the range of 191-210 MBq. 3. A method of claim 1, wherein the compound is detected by a gamma camera, positron emission tomography (PET), or single photon emission tomography (SPECT).